World’s Largest Heart Failure Study Finally Answers Questions About Nesiritide (DukeHealth.org)
Nov. 15, 2010
Results from the largest acute heart failure study ever conducted have resolved safety questions raised five years ago about the acute heart failure medication nesiritide (Natrecor), but more importantly illustrate the need for comprehensive, large, real world studies of investigational agents early in the course of development of new therapies, according to researchers at the Duke Clinical Research Institute.
Transfusion Rates Vary Extremely in Cardiac Bypass Surgery (DukeHealth.org)
Oct. 12, 2010
Transfusion rates for blood products used in a common heart surgery range from no patients to nearly all patients, and vary by hospital, according to findings from a group of researchers from Duke University Medical Center. The study, which looked at data from 102,470 patients in 798 hospitals, examined the variation in transfusion rates for red blood cells (RBCs), plasma and platelets, but the team didn't reach conclusions about how well patients fared if they did or didn't get a transfusion.
End of Life Trends in Heart Failure Care in the U.S. and Canada (DukeHealth.org)
Oct. 11, 2010
A new analysis of trends in end-of-life care for heart-failure patients reveals shifts in how care is provided, surprising use of diagnostic tests and procedures, and striking comparisons with Canada’s universal health care system, according to researchers at the Duke Clinical Research Institute.
Long-Awaited Questions Answered on Loop IV Diuretics Use (DukeHealth.org)
Mar. 16, 2010
The first trial to scrutinize diuretics used routinely in hospitalized heart failure patients shows current administration practices are equally effective, and higher doses yield better results with minimal risk to renal function, according to Duke University Medical Center researchers who presented the data today at the American College of Cardiology meeting.